Altered arsenic disposition in experimental nonalcoholic fatty liver disease

Drug Metabolism and Disposition

Volumn 40, Issue 9, 2012, Pages 1817-1824

  Canet, Mark J ^a   Hardwick, Rhiannon N ^a   Lake, April D ^a   Kopplin, Michael J ^a   Scheffer, George L ^b   Klimecki, Walter T ^a   Gandolfi, A Jay ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENATE SODIUM; ARSENIC; ARSENIC DERIVATIVE; ARSENIC METHYLTRANSFERASE; ARSENIC TRIOXIDE; CHOLINE; DIMETHYL ARSENIC; METHIONINE; METHYLTRANSFERASE; MONOMETHYL ARSENIC; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; C57BL 6 MOUSE; CELL TRANSPORT; CONTROLLED STUDY; LIPID DIET; LIVER LEVEL; LIVER METABOLISM; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEATOSIS; URINE LEVEL;

ANIMALS; ARSENATES; ARSENICALS; BIOTRANSFORMATION; CHOLINE DEFICIENCY; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENVIRONMENTAL POLLUTANTS; FATTY LIVER; KIDNEY; LIVER; MALE; METHIONINE; METHYLTRANSFERASES; MICE; MICE, INBRED C57BL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OXIDES;

EID: 84865182093     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046177     Document Type: Article

References (43)

1. Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, and Manautou JE (2008) Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology 250:82-88.
2. Ali R and Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41:265-278.
3. Bentley R and Chasteen TG (2002) Microbial methylation of metalloids: arsenic, antimony, and bismuth. Microbiol Mol Biol Rev 66:250-271. (Pubitemid 34625710)
4. Buchet JP, Geubel A, Pauwels S, Mahieu P, and Lauwerys R (1984) The influence of liver disease on the methylation of arsenite in humans. Arch Toxicol 55:151-154. (Pubitemid 14034032)
5. Caballero F, Fernández A, Matías N, Martínez L, Fucho R, Elena M, Caballeria J, Morales A, Fernández-Checa JC, and García-Ruiz C (2010) Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem 285:18528-18536.
6. Carew MW and Leslie EM (2010) Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis 31:1450-1455.
7. Carew MW, Naranmandura H, Shukalek CB, Le XC, and Leslie EM (2011) Monomethylarsenic diglutathione transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Drug Metab Dispos 39:2298-2304.
8. Csanaky I and Gregus Z (2003) Effect of selenite on the disposition of arsenate and arsenite in rats. Toxicology 186:33-50. (Pubitemid 36246618)
9. Dilda PJ and Hogg PJ (2007) Arsenical-based cancer drugs. Cancer Treat Rev 33:542-564. (Pubitemid 47355338)
10. Drobna Z, Naranmandura H, Kubachka KM, Edwards BC, Herbin-Davis K, Styblo M, Le XC, Creed JT, Maeda N, Hughes MF, et al. (2009) Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem Res Toxicol 22:1713-1720.
11. Drobná Z, Walton FS, Paul DS, Xing W, Thomas DJ, and Stýblo M (2010) Metabolism of arsenic in human liver: the role of membrane transporters. Arch Toxicol 84:3-16.
12. Feldstein AE (2010) Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 30:391-401.
13. Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, and Cherrington NJ (2009a) Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 613:119-127.
14. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, and Cherrington NJ (2009b) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
15. Gomez-Rubio P, Roberge J, Arendell L, Harris RB, O'Rourke MK, Chen Z, Cantu-Soto E, Meza-Montenegro MM, Billheimer D, Lu Z, et al. (2011) Association between body mass index and arsenic methylation efficiency in adult women from southwest U.S. and northwest Mexico. Toxicol Appl Pharmacol 252:176-182.
16. Gong Z, Lu X, Cullen WR, and Le XC (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J Anal At Spectrom 16:1409-1413. (Pubitemid 34026211)
17. Gyamfi MA, Damjanov I, French S, and Wan YJ (2008) The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol 75:981-995. (Pubitemid 351174111)
18. Hardwick RN, Fisher CD, Canet MJ, Lake AD, and Cherrington NJ (2010) Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293-2301.
19. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, and Cherrington NJ (2011) Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:2395-2402.
20. Hardwick RN, Fisher CD, Street SM, Canet MJ, and Cherrington NJ (2012) Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 40:450-460.
21. Heck JE, Nieves JW, Chen Y, Parvez F, Brandt-Rauf PW, Graziano JH, Slavkovich V, Howe GR, and Ahsan H (2009) Dietary intake of methionine, cysteine, and protein and urinary arsenic excretion in Bangladesh. Environ Health Perspect 117:99-104.
22. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
23. Jin Y, Zhao F, Zhong Y, Yu X, Sun D, Liao Y, Lv X, Li G, and Sun G (2010) Effects of exogenous GSH and methionine on methylation of inorganic arsenic in mice exposed to arsenite through drinking water. Environ Toxicol 25:361-366.
24. Kala SV, Kala G, Prater CI, Sartorelli AC, and Lieberman MW (2004) Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chem Res Toxicol 17:243-249. (Pubitemid 38252504)
25. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, and Lieberman MW (2000) The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275:33404-33408.
26. Kalhan SC, Edmison J, Marczewski S, Dasarathy S, Gruca LL, Bennett C, Duenas C, and Lopez R (2011) Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin Sci (Lond) 121:179-189.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321. (Pubitemid 40770284)
28. Kligerman AD, Doerr CL, Tennant AH, Harrington-Brock K, Allen JW, Winkfield E, Poorman-Allen P, Kundu B, Funasaka K, Roop BC, et al. (2003) Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ Mol Mutagen 42:192-205. (Pubitemid 37429756)
29. Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, and Cherrington NJ (2011) Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:1954-1960.
30. Leslie EM, Haimeur A, and Waalkes MP (2004) Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 279:32700-32708. (Pubitemid 39014729)
31. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35:1970-1978. (Pubitemid 47481594)
32. Lin S, Shi Q, Nix FB, Styblo M, Beck MA, Herbin-Davis KM, Hall LL, Simeonsson JB, and Thomas DJ (2002) A novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. J Biol Chem 277:10795-10803. (Pubitemid 34952833)
33. Loenen WA (2006) S-adenosylmethionine: jack of all trades and master of everything? Biochem Soc Trans 34:330-333.
34. Lorico A, Bertola A, Baum C, Fodstad O, and Rappa G (2002) Role of the multidrug resistance protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice. Biochem Biophys Res Commun 291:617-622. (Pubitemid 34687390)
35. Mandal BK, Ogra Y, and Suzuki KT (2001) Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem Res Toxicol 14:371-378. (Pubitemid 32367470)
36. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, and Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72-81.
37. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40 (Suppl 1):S17-S29.
38. Rosen BP and Liu Z (2009) Transport pathways for arsenic and selenium: a minireview. Environ Int 35:512-515.
39. Thomas DJ (2007) Molecular processes in cellular arsenic metabolism. Toxicol Appl Pharmacol 222:365-373.
40. Thomas DJ, Styblo M, and Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176:127-144. (Pubitemid 33015863)
41. Vahter M and Marafante E (1987) Effects of low dietary intake of methionine, choline or proteins on the biotransformation of arsenite in the rabbit. Toxicol Lett 37:41-46.
42. Wang TC, Jan KY, Wang AS, and Gurr JR (2007) Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells. Mutat Res 615:75-86. (Pubitemid 46075134)
43. Yoshida T, Yamauchi H, and Fan Sun G (2004) Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol 198:243-252. (Pubitemid 38969953)